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Abstract 
We report the synthesis of linear and branched (1→4)-D-galactans. Four tetra- and one pentasaccharide 
were accessed by adopting a procedure of regioselective ring opening of a 4,6-O-naphthylidene 
protecting group followed by glycosylation using phenyl thioglycoside donros. The binding of the 
linear pentasaccharide with galectin-3 is also investigated by determination of a co-crystal structure. 
The binding of the  (1→4)-linked galactan to Gal-3 highlights oligosaccharides of pectic galactan, 
which is abundant in the human diet, as putative Gal-3 ligands.  
  
Keywords 
Plant oligosaccharides, RG-I, (1→4)-D-galactan, CRD, galectin-3.  
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Introduction 
Carbohydrates are highly complex structures synthesized and metabolized by nearly all organisms. In 
particular, plant cell wall polysaccharides exhibit a broad diversity in their saccharide composition. 
One major class of polysaccharides present in plants is pectins, which are divided into three main types, 
namely homogalacturonan (HG), rhamnogalacturonan (RG) I and II. RG-I is a heteropolymer with a 
backbone of alternating α-linked L-rhamnose and D-galacturonic acid residues with the extensive 
branching of galactans, arabinogalactans, and arabinans.1,2 It has been shown that certain pectins have 
health promoting effects, in particular for the inhibition of metastasis and cancer cell growth.3,4 These 
health benefits are assumed to be linked to their interaction with galectins.5,6 Galectins are 
carbohydrate- binding proteins with a defined carbohydrate recognition domain (CRD) which has a 
high affinity for glycans containing β-D-galactose residues. The galectin family is classified by the 
organization of the CRDs into three distinct types: prototype, chimera and tandem repeat. The only 
galectin of the chimera type is galectin-3 (Gal-3).3,7 The unique N-terminal coiled-coil region of Gal-3 
is responsible for oligomerization.8 Consequently, the binding of galactose can occur either in a 
monomeric or oligomeric form of the lectin.9 The binding affinity of Gal-3 increases if galactose is 
linked to other saccharides, in particular to N-acetyl-lactosamine-containing glycoconjugates.10,11 Gal-3 
is involved in several biological processes such as cell-cell interactions, cell development and 
proliferation as well as apoptosis.10,12 Therefore, changes in Gal-3 expression levels are linked to the 
development of cancer and have been shown to have a role in metastasis.13 
Recently, Stegmayr et al. tested RG-1 polysaccharides as well as well-defined synthetic 
oligosaccharides as potential galectin-3 inhibitors using a fluorescence anisotropy assay. They 
generally found weak inhibition and their results suggest that the activity is not due to interaction with 
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the galectin carbohydrate binding site.14 We have engaged in a research program with two main 
purposes: 1) to develop efficient synthetic methods to target well-defined oligosaccharides that are 
representative of microdomains from the heterogeneous and complex pectic polysaccharides; and 2) to 
probe interactions between these oligosaccharides and biologically important proteins, including 
monoclonal antibodies and lectins. In the current study, we wanted to synthesize both naturally 
occurring branched and linear beta-linked oligogalactans found in the RG-I backbone of pectin, as well 
as analogues with one or two alpha-linkages. We decided to target the linear (1, 2) and branched (3–5) 
galactans shown in Figure 1, in order to obtain structures with a size that is synthetically feasible while 
retaining likelihood of protein binding. We furthermore desired to probe the interaction between the 
oligosaccharides and galectin-3, starting with the linear galactan 2. 
 
Figure 1: Target structures 
Results and Discussion 
To glycosylate the C4- and C6-OH in a sequential manner, which was needed for the branched 
structures 3–5, it was necessary to find a protecting group strategy that allowed regioselective 
deprotection. The benzylidene acetal is often used for 4,6-protection since it can be regioselectively 
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opened under reductive conditions.15–17 However, its use is limited by the fact that the resulting benzyl 
ether is a permanent protecting group in most strategies. Several other acetals have been developed that 
allow selective deprotection of the corresponding ether. The most common is the 
p-methoxybenzylidene acetal.18–20 Regioselective cleavage of the p-methoxybenzylidene acetal results 
in a p-methoxybenzyl (PMB) group, which can be cleaved using oxidative conditions without affecting 
benzyl- and acyl protecting groups.21,22 Unfortunately, the p-methoxybenzylidene acetal is much more 
acid labile than its unsubstituted counterpart.23,24 Instead it was decided to use the less common 
(2-naphthyl)methylene acetal as temporary protecting group. This acetal and its corresponding ether are 
less sensitive to acid, but due to the electron-rich ring system they still have many of PMB’s 
advantages.19 The regioselective reductive opening of the acetal with NaCNBH3/HCl-OEt2 results in 
the C6-O-NAP ether, which can be removed by oxidation with DDQ.25,26 This feature would make it 
possible to selectively deprotect first the 4-position and later on selectively cleave the C6-O-NAP. With 
this in mind, the two monosaccharide building blocks 627 and 728 were synthesized according to 
literature procedures (see Supporting Info).  
O
HO OH
OH
O
HO O
OH
RO
OH
OR'
1 R = β-1,4-D-Gal-β-D-Gal; R' = H
2 R = β-1,4-D-Gal-β-1,4-D-Gal-β-D-Gal; R' = H
3 R = β-D-Gal; R' = β-D-Gal
4 R = β-D-Gal; R' = α-D-Gal
5 R = α-D-Gal; R' = α-D-Gal
O
AcO SPh
OAc
O
O
O
BnO OBn
OBn
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6 7
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Scheme 1: Retrosynthetic analysis 
NIS/TESOTf-promoted29 coupling of donor 6 and acceptor 7 in 1:1 CH2Cl2/CH3CN afforded 
β-glycoside 8 in 77% yield (Scheme 2). A regioselective reductive opening of the naphthylidene acetal 
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was achieved by treatment with NaCNBH3/HCl·OEt2
30 to give the disaccharide acceptor 9 in 83% 
yield. 
Donor 6 was coupled to 9 under the same conditions, to give the β-linked trisaccharide 11 (Scheme 2) 
in 81% yield. A glycosylation between disaccharide 9 and known donor 1031 led to the α,β-linked 
trisaccharide 13 in a comparable yield. In the latter case, the use of a 1:1 CH2Cl2/Et2O solvent mixture 
resulted in improved α-selectivity.32,33 
The NAP group on both trisaccharides 11 and 13 was selectively removed by oxidative cleavage with 
DDQ in CH2Cl2/MeOH/H2O (3:1:0.25).
34,35 However, it was observed that addition of 20% methanol 
was crucial to avoid simultaneous deprotection of the benzyl groups. It is noteworthy that the 
naphthylidene acetal in 11 is stable under these conditions.19 
O
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Scheme 2: Synthesis of trisaccharides 12 & 14 
Coupling of the two trisaccharides 12 and 14 to either donor 6 or donor 10 using standard conditions 
afforded the three tetrasaccharides 15, 16 and 17 in good yields (75-81%, Scheme 3). Trisaccharide 11 
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was further regioselectively deprotected using NaCNBH3/HCl·OEt2 and subsequently coupled with 6 to 
give the linear tetrasaccharide 18 (Scheme 3). Repeating the deprotection and coupling cycle led to 
pentasaccharide 19.  
Transesterification with NaOMe/MeOH followed by hydrogenolysis over Pd/C gave the four 
unprotected tetrasaccharides 1, 3–5 and pentasaccharide 2. A high amount of palladium (20 mol%) and 
addition of acetic acid was necessary to obtain full conversion due to catalyst poisoning by 
2-methylnaphthalene.25 
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Scheme 3: Synthesis of target oligogalactans 1-5 
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The unprotected oligosaccharides were conjugated to BSA and immobilized on microarrays together 
with other plant oligosaccharides in order to characterize protein-carbohydrate interactions. The results 
of the antibody screening are summarized in the work of Pedersen et al.36 The linear saccharide 2 was 
further used to characterize the galactosyltransferase activity of galactan synthase 1 (GALS1).37  
To investigate the CRD of Gal-3, we decided to investigate co-crystallization with synthetic 
oligosaccharides. It has been hypothesized that the carbohydrate recognition domain of Gal-3 can 
accommodate a linear tetrasaccharide.38 If this is the case, oligosaccharides of four or more residues are 
likely to have higher binding affinity than N-acetyl-lactosamine (LacNAc), which has previously been 
used as a scaffold for the development of Gal-3 inhibitors. Consequently, it was decided to start by co-
crystallizing Gal-3 in complex with the linear pentasaccharide 2. 
 
The co-crystallization presented some challenges. Lactose contaminants in the first protein sample 
occupied the binding site and thereby precluded co-crystallization with the ligand, already indicating 
weak binding of the pentasaccharide. However, use of a lactose-free batch of protein and a higher 
ligand concentration made it possible to obtain a crystal structure of Gal-3 in complex with 
pentasaccharide 2 at 1.4 Å resolution. The structure is shown in Figure 2. Contrary to our expectations, 
Gal-3 only binds to two of the five galactose residues. The remaining residues are too flexible to be 
observed. Moreover, the second galactose residue has much weaker electron density than the first one 
(Figure 2B). Since the first residue has full occupancy and there is presumably no hydrolysis of the 
ligand, this means that the second residue is significantly more flexible. Given that the binding site has 
evolved to bind glucose at the second site, it is perhaps not surprising that galactose binds with lower 
affinity. The C4-epimerization that relates galactose to glucose results in a configuration in which, no 
matter what the torsion angle around the glycosidic bond, the second galactose moiety is unable to 
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achieve the interactions made by glucose. Instead, the second galactose adopts a conformation in which 
the 6-hydroxymethyl functional group is projected towards the protein instead of the C3-hydroxyl 
group in glucose. Significant interactions observed between the C3-OH of glucose and Arg162/Glu184 
are lost, and a water molecule binds there instead (Figure 2C). O1 of the second galactose is projected 
away from the binding surface, making it difficult for further β-(1→4)-coupled galactose units to make 
contact with the protein. The structure demonstrates that the central sugar binding site (sites C and D in 
the accepted nomenclature of Leffler et al.38) cannot tightly bind β-(1→4)-coupled galactose units. 
This is consistent with predictions made by Stegmayr et al. on the basis of molecular modelling14. 
Structures are available of larger glycans in complex with the Gal-3 CRD, e.g. the tetrasaccharides 
lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) that form the core of some glycosphingolipids 
present on mammalian cells and the acetamido ganglioside α-2,3-sialyllactose.39 However, all of these 
contain a lactose (Gal-β(1→4)-Glc) disaccharide in sites C and D, and additional interactions are made 
with the protein in site B through linkage to the 3-OH of Gal. Accommodation of other sugars in site D 
is demonstrated by the complexes of Gal-3 CRD with various derivatives of the Thomsen-Freidenreich 
antigen (Gal-β(1→3)-GalNAc-α(1→O)-Ser/Thr).40 The β-(1→3)-linkage orients the GalNAc moiety 
in site D such that O4 interacts with Glu184 instead of O3 in lactose; further stabilizing interactions are 
made by water-mediated hydrogen bonds to the N-acetyl group. Furthermore, the success of 
thiodigalactosides as very high affinity inhibitors of Gal-341,42 demonstrates that digalactosides can 
bind to sites C and D; however in this case the galactose units are β-(1→1)-linked, allowing a 
reorientation of the second galactose such that O2 is able to mimic the interactions of 3-OH in glucose 
perfectly. 
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Nevertheless, even though the binding of the β-(1→4)-linked galactan to galectin-3 seems to be poor 
based on the crystal structure, consistent with earlier work on β-(1→4)-linked Gal disaccharides using 
fluorescence anisotropy14, this does not exclude it as  a potential ligand of Gal-3. Since Gal-3 is a 
chimeric galectin, binding to several digalactan motifs could result in a significantly higher total 
binding avidity.43 However, since only two galactose residues of 2 were shown to bind to Gal-3, we 
decided not to pursue co-crystallization with the remaining four oligosaccharides (1, 3–5) since such 
studies were highly unlikely to lead to further insights. 
 
 
Figure 2: A) Overall view of the binding of the pentasaccharide to the Gal-3 CRD. B) Electron density 
for the first two galactose moieties of the pentasaccharide co-crystallized with the Gal-3 CRD. To 
illustrate the weakness of the density for the second galactose, the electron density map is contoured at 
two different levels around the saccharide: 1.0 σ (black) and 0.5 σ (orange). For the water molecules 
the map is contoured at 1.0 σ. Important residues in the binding site are labelled. The water molecule 
that binds in the position of the glucose 3-OH in lactose is labelled W. C) Hydrogen-bonding 
interactions of the first two Gal moieties with Gal-3 are shown as dotted grey lines. For comparison, 
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the lactose complex (PDB ID 3ZSJ, Saraboji et al., Biochemistry 2012) is shown as thin grey sticks. It 
can clearly be seen that the well-ordered water molecule replaces O3 of glucose. 
Conclusion 
An efficient synthetic route to smaller linear and branched oligogalactans have been developed. The 
4,6-naphthylidene group proved useful, as it could be reductively opened to provide 6-O-NAP 
protected acceptors or removed entirely to give diol acceptors. Glycosyl donors with either benzyl or 
acetyl protection at the 2-position provided α- and β-selective glycosylation reactions, respectively. 
Finally, the linear pentasaccharide 2 was co-crystallized with Gal-3, resulting in an X-ray crystal 
structure at 1.4 Å resolution. The structure confirmed that galactans are ligands for Gal-3 – but also that 
the linear, beta-1,4 galactans bind poorly, as only two of the five galactose residues were resolved in 
the structure. The work described here should pave the way for future studies of both pectic galactans 
and their analogues as well as of ligands for Gal-3. 
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